Biodesix Inc. (BDSX) Files $250M Mixed Shelf
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Biodesix Inc. (BDSX) Reports Publication Highlighting Interim Data from the INSIGHT Study Assessing the Clinical Effectiveness of VeriStrat
November 18, 2021 6:01 AM ESTBiodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced new interim data published from the large multi-center observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects) (NCT03289780) utilizing its novel predictive and prognostic blood-based host immune classifier (the VeriStrat test) to... More
Biodesix Inc. (BDSX) Tops Q3 EPS by 5c
November 15, 2021 7:47 AM ESTBiodesix Inc. (NASDAQ: BDSX) reported Q3 EPS of ($0.41), $0.05 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $6.5 million versus the consensus estimate of $7.37 million.
For earnings history and earnings-related data on Biodesix Inc. (BDSX) click here.
... More